Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||IPN60090 + Paclitaxel|
Limited information is currently available on IPN60090 (Apr, 2019).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|IPN60090||IPN60090 is an inhibitor of inhibitor of glutaminase, which prevents the conversion of glutamine to glutamate to inhibit tumor cell proliferation (NCI Drug Dictionary).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03894540||Phase I||IPN60090 IPN60090 + Pembrolizumab IPN60090 + Paclitaxel||A Phase I, Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours||Recruiting|